News

Products


 

Diagnostic Ultrasound System

The Accuvix V20 ultrasound system provides high-resolution 3-D and 4-D images. The system combines computed tomography and magnetic resonance imaging with 3-D ultrasound to achieve a multislice view. An oblique view extended feature offers specific segmentation of anatomical structures within the 3-D data set. The 3D Orientation Cube is designed to assist both the new as well as the experienced 3-D imaging user in achieving right/left, anterior/posterior, and cephalic/caudal orientation. The ergonomic design includes a 17-inch LCD flat screen monitor with an articulated arm and a 10.4-inch touch screen.

Medison America Inc.

www.medisonusa.com

Generic Plan B

A generic version of the Plan B emergency contraceptive (0.75 mg levonorgestrel) has been approved by the Food and Drug Administration for prescription use in women aged 17 years and younger. As with the original Plan B, the generic tablets are indicated for the prevention of pregnancy after unprotected sex or contraceptive failure. The generic Plan B does not provide protection against any sexually transmitted diseases, and it does not terminate an existing pregnancy. The generic levonorgestrel will be marketed as Next Choice.

Watson Pharmaceuticals Inc.

www.watson.com

OTC Mobile Reference

Ob.gyns. can use an over-the-counter mobile reference tool to help women make informed decisions about OTC medications. The Epocrates OTC drug module allows doctors to use the Internet or a handheld device such as a Blackberry to identify potential drug interactions and indications for OTC medications. Examples include locating which OTC cough and cold products are safe during pregnancy and breastfeeding and identifying appropriate sugar-free cough suppressants for women with gestational diabetes.

Epocrates Inc.

www.Epocrates.com

New Option for Pain Relief

Nucynta (tapentadol) CII is now available in 50-mg, 75-mg, and 100-mg tablets for the treatment of moderate to severe acute pain in patients 18 years and older. Nucynta, a mu-opioid receptor agonist, was approved by the Food and Drug Administration as a schedule II drug. It is recommended that the product be taken every 4–6 hours, with a maximum 24-hour dose of 700 mg on the first day and 600 mg thereafter. The drug is contraindicated in patients with respiratory depression, severe bronchial asthma, and renal or hepatic impairment, among other conditions. It also is contraindicated in patients using monoamine oxidase inhibitors. It is not recommended for use during pregnancy, labor, or breastfeeding.

Ortho-McNeil-Janssen Pharmaceuticals Inc.

www.nucynta.com

Next Article: